重组人干扰素α-2b治疗肛门生殖器疱疹的临床观察

Clinical Observation on the Therapeutic Efficacy of Recombinative Interferon α-2b in the Treatment of Anogenital Herpes

为观察重组人干扰素α-2b肌肉注射治疗肛门生殖器疱疹的临床疗效，对40例肛门生殖器疱疹采用重组人干扰素α-2b300万U肌肉注射治疗（治疗组），隔日1次；30例肛门生殖器疱疹患者口服阿昔洛韦治疗（对照组），200mg／次，5次／d；并对疗效进行对比观察。结果显示，治疗组治疗后年复发次数下降58．5％，明显优于对照组（18．5％），P〈0．01。治疗组IL-4、IL-10含量下降，IL-12、IL-18含量上升；对照组无明显变化。结果表明，重组人干扰素α-2b肌肉注射治疗肛门生殖器疱疹复发率低，可调节机体免疫功能。

The objective of this study was to investigate the curative effect of recombinative interferon α-2b on anogenital herpes. Forty patients with anogenital herpes were injected with recombinative interferon α- 2b（3 000 000 units,im）,once every other day（the study group）,and 30 patients with anogenital herpes took Aciclovir orally, 200mg/time, 5times/day（the control group）. The therapeutic efficacy of the two drugs in the two groups was observed. As results,the yearly recurrence was reduced by 58.5% in the study group, greatly better than that in the control group （18.5 %）（ P 〈0.01 ） ;and interleukin-4 （IL-4） and IL-10 decreased in content while IL-12 and IL-18 increased in the study group; the content of the above-mentioned interleukins had no change in the control group. It is concluded that interferon α-2b（im） can ensure a lower recurrence due to its regulation on human immune function in the treatment of anogenital herpes.